JP7498702B2 - Ｔｌｒ８アゴニスト - Google Patents
Ｔｌｒ８アゴニスト Download PDFInfo
- Publication number
- JP7498702B2 JP7498702B2 JP2021515104A JP2021515104A JP7498702B2 JP 7498702 B2 JP7498702 B2 JP 7498702B2 JP 2021515104 A JP2021515104 A JP 2021515104A JP 2021515104 A JP2021515104 A JP 2021515104A JP 7498702 B2 JP7498702 B2 JP 7498702B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- acceptable salt
- tlr8
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811094969.4 | 2018-09-19 | ||
| CN201811094969 | 2018-09-19 | ||
| PCT/CN2019/106687 WO2020057604A1 (zh) | 2018-09-19 | 2019-09-19 | Tlr8激动剂 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501350A JP2022501350A (ja) | 2022-01-06 |
| JP2022501350A5 JP2022501350A5 (https=) | 2022-09-21 |
| JPWO2020057604A5 JPWO2020057604A5 (https=) | 2022-09-21 |
| JP7498702B2 true JP7498702B2 (ja) | 2024-06-12 |
Family
ID=69888288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515104A Active JP7498702B2 (ja) | 2018-09-19 | 2019-09-19 | Ｔｌｒ８アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12054482B2 (https=) |
| EP (1) | EP3854794B1 (https=) |
| JP (1) | JP7498702B2 (https=) |
| KR (1) | KR102856089B1 (https=) |
| CN (2) | CN112805283B (https=) |
| AU (1) | AU2019344868B2 (https=) |
| CA (1) | CA3112953A1 (https=) |
| ES (1) | ES2999323T3 (https=) |
| PH (1) | PH12021550601A1 (https=) |
| SG (1) | SG11202102641RA (https=) |
| WO (1) | WO2020057604A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
| EP4122931B1 (en) * | 2020-03-18 | 2025-07-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline form of tlr8 agonist |
| CN116472047B (zh) * | 2021-11-05 | 2025-06-17 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011513413A (ja) | 2008-03-03 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｔｌｒ活性モジュレーターとしての化合物および組成物 |
| JP2014516958A (ja) | 2011-05-18 | 2014-07-17 | ヤンセン・アールアンドデイ・アイルランド | ウイルス感染およびその他の疾患を治療するためのキナゾリン誘導体 |
| JP2017509667A (ja) | 2015-03-04 | 2017-04-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様レセプター調節４，６−ジアミノ−ピリド［３，２−ｄ］ピリミジン化合物 |
| WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
-
2019
- 2019-09-19 SG SG11202102641RA patent/SG11202102641RA/en unknown
- 2019-09-19 ES ES19862693T patent/ES2999323T3/es active Active
- 2019-09-19 AU AU2019344868A patent/AU2019344868B2/en active Active
- 2019-09-19 CN CN201980052513.8A patent/CN112805283B/zh active Active
- 2019-09-19 KR KR1020217011377A patent/KR102856089B1/ko active Active
- 2019-09-19 US US17/276,920 patent/US12054482B2/en active Active
- 2019-09-19 EP EP19862693.9A patent/EP3854794B1/en active Active
- 2019-09-19 JP JP2021515104A patent/JP7498702B2/ja active Active
- 2019-09-19 WO PCT/CN2019/106687 patent/WO2020057604A1/zh not_active Ceased
- 2019-09-19 CN CN202211301510.3A patent/CN115650979A/zh active Pending
- 2019-09-19 CA CA3112953A patent/CA3112953A1/en active Pending
-
2021
- 2021-03-17 PH PH12021550601A patent/PH12021550601A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011513413A (ja) | 2008-03-03 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｔｌｒ活性モジュレーターとしての化合物および組成物 |
| JP2014516958A (ja) | 2011-05-18 | 2014-07-17 | ヤンセン・アールアンドデイ・アイルランド | ウイルス感染およびその他の疾患を治療するためのキナゾリン誘導体 |
| JP2017509667A (ja) | 2015-03-04 | 2017-04-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様レセプター調節４，６−ジアミノ−ピリド［３，２−ｄ］ピリミジン化合物 |
| WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3854794A1 (en) | 2021-07-28 |
| JP2022501350A (ja) | 2022-01-06 |
| AU2019344868A1 (en) | 2021-04-15 |
| AU2019344868B2 (en) | 2024-06-27 |
| ES2999323T3 (en) | 2025-02-25 |
| US12054482B2 (en) | 2024-08-06 |
| CN112805283A (zh) | 2021-05-14 |
| WO2020057604A1 (zh) | 2020-03-26 |
| SG11202102641RA (en) | 2021-04-29 |
| PH12021550601A1 (en) | 2021-11-29 |
| KR102856089B1 (ko) | 2025-09-04 |
| CN115650979A (zh) | 2023-01-31 |
| KR20210060567A (ko) | 2021-05-26 |
| CA3112953A1 (en) | 2020-03-26 |
| US20210371414A1 (en) | 2021-12-02 |
| EP3854794A4 (en) | 2022-06-15 |
| CN112805283B (zh) | 2022-09-20 |
| EP3854794B1 (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102198128B1 (ko) | 바이러스 감염 및 추가 질환의 치료를 위한 아실아미노피리미딘 유도체 | |
| JP6839104B2 (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| CA3230542A1 (en) | Novel ras inhibitors | |
| EP2485737B1 (en) | Novel trpa1 antagonists | |
| JP7747614B2 (ja) | Ｐｄ－ｌ１阻害剤としてのインダン | |
| JP2019527202A (ja) | 免疫調節化合物 | |
| JP7498702B2 (ja) | Ｔｌｒ８アゴニスト | |
| AU2014311148B2 (en) | Vancomycin derivative, and preparation method and application thereof | |
| TW201700098A (zh) | 治療ｂ型肝炎病毒的方法 | |
| CN112839929B (zh) | Tlr8激动剂 | |
| US20210009612A1 (en) | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
| RU2800877C2 (ru) | Агонист tlr8 | |
| HK40048022A (en) | Tlr8 agonist | |
| HK40048022B (en) | Tlr8 agonist | |
| CN119264114A (zh) | 一种nlrp3抑制剂及其制备方法和应用 | |
| WO2025252163A1 (zh) | 一种哒嗪并环衍生物及其在医药上的应用 | |
| NZ709769A (en) | 2-aminopyrimidine derivatives for the treatment of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220912 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220912 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7498702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |